Assessment of Endothelial Function, Apolipoproteins and Adiponectin

NCT01300390 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2016-05-17

No results posted yet for this study

Summary

The overall hypothesis is that endothelial function, apolipoprotein levels and adiponectin levels are accurate predictors of underlying cardiovascular disease in patients with end-stage liver disease, in whom standard tools for the diagnosis of and screening for cardiovascular disease are of limited utility.

Conditions

  • Cirrhosis

Sponsors & Collaborators

Principal Investigators

  • Kymberly Watt, MD · Mayo Clinic

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2015-10-31
Completion
2015-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01300390 on ClinicalTrials.gov